drugset
drugset / Trial / NCT05242042

JT001 (VV116) for the Early Treatment of COVID-19

NCT05242042 ↗

Phase 2/3 Terminated 381 enrolled Shanghai JunTop Biosciences Co., LTD Sponsor GmbH · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of JT001 (VV116) for the early Treatment of Coronavirus Disease 2019 (COVID-19) in participants with mild to moderate COVID-19, at high risk for progression to severe COVID-19, including death.

Timeline

Start
2022-01-28
Primary completion
2023-03-23
Completion
2023-03-23

Outcome

Outcome not reported

Stopped: “Based on the current number of COVID-19 cases and the approval of COVID-19 treatment drugs , the research team is facing great challenges, and it is decided to terminate this study”

Drugs

EvaluationDrugModalityDoseRoute
Subject JT001 Small molecule — Oral

Indications

No indication recorded.